Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 9,301–9,400 of 15,747
Melamed, J. R., Muscat-Rivera, J., Kegel, M., Chaboub, L. S., Perez‐Tremble, R., Bhalla, N. S., Ni, H., Sun, H., & Weissman, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.17.683125 · Cited by 10
“28,30,31 36 The anionic phospholipids DOPS, BMP, and DOPG were selected for their compatibility with standard LNP formulations.”
Post-Trial Access: Historical Analysis Considering the Experience of COVID-19 Pandemic
Kurihara, C., Greco, D. B., & Dhai, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-6163-4_12 · Cited by 6
Preliminary evaluation of a novel serotype O foot-and-mouth disease mRNA vaccine
Zhao, J., Xiao, P., Xin, A., Zhu, H., Wang, H., Xiao, J., & Gao, H. X. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1503191 · Cited by 6
“…staining (Figure 6), clinical evaluations (Figure 3F) following simultaneous vaccination demonstrated that the mRNA vaccine provided a safe and effective immune response, which was consistent with the outcomes of COVID-19 mRNA vaccine (Polack et al., 2020; Baden et al., 2021; Baden et al., 2024).”
Influenza mRNA vaccine reduces pathogenicity and transmission of A(H5N1) virus in a ferret model
Hatta, M., Brock, N., Hauguel, T., Feng, C., Huang, Y., Ritter, J. M., Hatta, Y., Keller, M. W., de Souza, I. P., Hossain, J., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01318-3 · Cited by 9
Choi, Y. S., Felgner, J. H., Jan, S., Hernandez‐Davies, J. E., Davies, D. H., & Kwon, Y. J. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02834h · Cited by 5
Blunted humoral response after mRNA vaccine in patients with haematological malignancies
Kamboj, M. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00197-6 · Cited by 5
Rolak, S. C., Said, A., German, M. N., Hayney, M. S., & Caldera, F. (2022) · PubMed · Cited by 6
Singer, S. R., Angulo, F. J., Swerdlow, D. L., McLaughlin, J. M., Hazan, I., Ginish, N., Anis, E., Mendelson, E., Mor, O., Zuckerman, N. S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3904701 · Cited by 5
Specific immune responses after BNT162b2 mRNA vaccination and COVID-19 infection
Arientová, S., Matúšková, K., Bartoš, O., Holub, M., & Beran, O. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1271353 · Cited by 5
Prior COVID‐19 vaccination and reduced risk of cerebrovascular diseases among COVID‐19 survivors
Chen, S., Hsieh, T. Y. J., Hung, Y., Oh, J. W., Chen, S.-F., Wang, S., Chang, R., & Wei, J. C. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29648 · Cited by 7
“…reported thromboembolic ‐ related side effects, which might have a negative impact on immunization rates, 16 comprehensive phase ‐ 3 clinical trials 17 – 19 and population ‐ based observational study 20 have not identified a significant causal role or association in monovalent 21,22 and bivalent…”
BackgroundCOVID-19 vaccine safety monitoring in low and middle income countries – Time for a bold new approach
Straus, W. L., & Rubin, H. N. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.053 · Cited by 5
Brain tumor patients and COVID-19 vaccines: results of an international survey
Voisin, M. R., Oliver, K. R., Farrimond, S., Chee, T., O’Halloran, P. J., Glas, M., International Brain Tumour Alliance (IBTA) Senior Advisors, Arzbaecher, J., Kruchko, C., Maher, M. E., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac063 · Cited by 5
Choi, Y., Lim, J., Bea, S., Lee, J., Choi, J. Y., Roh, S., Lee, D. I., Na, J. O., & Kim, H. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae335 · Cited by 7
Pêgo, A. C., Lima, I. S., & Gozzelino, R. (2024) · COVID · doi:10.3390/covid4020014 · Cited by 7
Wagner, M. J., Hennessy, C., Beeghly, A., French, B. C., Shah, D. P., Croessmann, S., Vilar‐Compte, D., Ruíz‐García, E., Ingham, M. A., Schwartz, G. K., et al. (2022) · Cancers · doi:10.3390/cancers14174334 · Cited by 5
Ellison, T. J., Talbott, G. C., & Henderson, D. R. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.006 · Cited by 6
SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients
Memenga, F., Kueppers, S. T., Borof, K., Kirchhof, P. F., Duengelhoef, P. M., Barten, M. J., Lütgehetmann, M., Berisha, F., Fluschnik, N., Becher, P. M., et al. (2023) · Transplant International · doi:10.3389/ti.2023.10883 · Cited by 5
Bellinvia, A., Aprea, M. G., Portaccio, E., Pastò, L., Razzolini, L., Fonderico, M., Addazio, I., Betti, M., & Amato, M. P. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06287-2 · Cited by 6
“In our study, we obtained similar data, and we further analyzed the reported AEs identifying a more than doubled rate of systemic AEs after the second dose, consistent with that reported in the RCTs [28, 29].”
BackgroundResultInfluentialThe Psychological Gains from COVID-19 Vaccination: Who Benefits the Most?Preprint
Bagues, M. F., & Dimitrova, V. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3954601 · Cited by 4
“In our setup, this possibility is in principle limited, given that individuals received their first jab just a few weeks before the survey and clinical trials indicate that COVID vaccines are ine↵ective during the first weeks (Polack et al., 2020).”
BackgroundInfluentialEclerová, V., Sen, D., & Přibylová, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-01467-4 · Cited by 7
“After infection with an infectious disease, individuals may experience a spectrum of symptoms, ranging from mild to severe (for COVID-19, see meta-analyses 30,31 , clinical studies 32,33 or nation-wide data analyses 29,34 ).”
COVID-19 immunization threshold(s): an analysisPreprint
Balbás, L. A. B., Gil-Conesa, M., Balbás, B. B., Jiménez, A. A., & Rodríguez‐Caravaca, G. (2021) · medRxiv · doi:10.1101/2021.01.02.20248596 · Cited by 5
Comparison of the 2021 COVID-19 Roadmap Projections against Public Health Data in England
(2022) · doi:10.1101/2022.03.17.22272535 · Cited by 5
“[33] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, et al.”
BackgroundLeding, C., Clausen, C. L., Roldgaard, M. S., & Benfield, T. (2023) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2023.2267134 · Cited by 5
“Patients admitted seven days or more after the first dose of the COVID-19 vaccine were categorised as partially vaccinated, and patients admitted seven days or more after the second dose were categorised as fully vaccinated [17].”
BackgroundCOVID-19 and immunity: quo vadis?
Miyasaka, M. (2021) · International Immunology · doi:10.1093/intimm/dxab008 · Cited by 6
Song, S., Liu, Z., Guo, L., Wang, Y., Liu, H., Yang, M., & Chen, G. (2024) · Journal of Flow Chemistry · doi:10.1007/s41981-024-00316-1 · Cited by 5
“• The Reynolds number was found to be a crucial factor influencing the sizes of poly A/bPEI cores and LPP NPs. vaccine have demonstrated the versatility, safety, and efficacy of LNPs [4].”
COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA
Krantz, M. S., & Phillips, E. J. (2022) · Murdoch University Research Portal · Cited by 5
Duhen, R., Beymer, M., Jensen, S. M., Abbina, S., Abraham, S., Jain, N., Thomas, A. M., Geall, A. J., Hu, H., Fox, B. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896310 · Cited by 6
COVID-19 Incidence and Vaccine Effectiveness in University Staff, 1 March 2020–2 April 2022
Cegolon, L., Negro, C., Pesce, M., & Filon, F. L. (2023) · Vaccines · doi:10.3390/vaccines11020483 · Cited by 6
Donadio, C., Rainone, A., Gouronnec, A., Belmin, J., & Lafuente‐Lafuente, C. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.04.004 · Cited by 5
Comparative efficacy of leading COVID-19 vaccines: A network meta-analysis
Rai, S., & Tripathi, S. S. (2025) · The Indian Journal of Medical Research · doi:10.25259/ijmr_750_2024 · Cited by 6
Wang, C., Tang, X., Jiang, C., Zhang, Y., Han, B., Sun, Y., Guo, J., Peng, H., Wang, Z., Wang, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1530736 · Cited by 6
[Reverse vaccinology: strategy against emerging pathogens].
Monterrubio-López, G. P., & Delgadillo-Gutiérrez, K. (2021) · PubMed · Cited by 12
Isolated thrombosis after COVID-19 vaccination: case series
Al-Ahmad, M. S., Rasheed, M. A., Altourah, L., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-021-03285-6 · Cited by 5
“In conclusion, isolated thrombosis was not reported as one of the vaccines adverse events in the earliest vaccine randomized controlled trials [9, 17].”
BackgroundSantiago, J. M., & Santos, A. R. (2022) · International Journal of Public Health Science (IJPHS) · doi:10.11591/ijphs.v11i2.21169 · Cited by 7
Passaretti, C. L., Priem, J. S., Agner, T. G., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.020 · Cited by 5
“Our results are consistent with previous research on vaccine effectiveness in HCWs [7].”
Vollenberg, R., Lorentzen, E. U., Kühn, J., Nowacki, T. M., Meier, J. A., Trebicka, J., & Tepasse, P. (2023) · Vaccines · doi:10.3390/vaccines11091411 · Cited by 6
Danjuma, M. I.-M., Sayed, R., Aboughalia, M., Hassona, A., Elsayed, B. M. S., Elshafei, M. N., & Elzouki, A.-N. Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20155 · Cited by 6
“Successful immunization with a variety of approved Coronavirus Disease 2019 (COVID-19) vaccines has significantly contributed to containing both the spread and the adverse consequences of this nascent infection [3,4].”
Optic neuritis secondary to the Pfizer-BioNTech-162b2 COVID-19 vaccine managed with plasmapheresis
Shah, P. P., Gelnick, S., Zhu, D., et al. (2022) · Oman Journal of Ophthalmology · doi:10.4103/ojo.ojo_354_21 · Cited by 5
“[2] In August 2021, the Pfizer COVID‑19 vaccine became the first of its type approved by the U.S. Food and Drug Administration, which even suggested benefit of a third dose for certain groups, further promoting its safety and effectiveness.”
Introduction of the BNT162b2 vaccine during a COVID-19 nursing home outbreak
McEllistrem, M. C., Clancy, C. J., Buehrle, D. J., LUCAS, A. E., Pruskowski, J. A., Handler, S. M., & Decker, B. K. (2021) · American Journal of Infection Control · doi:10.1016/j.ajic.2021.07.019 · Cited by 4
“Symptoms included new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhea, or vomiting.(13) Residents in the vaccine analysis were censored if they developed asymptomatic or symptomatic COVID-19 confirmed with an RT-PCR test…”
Impact of COVID-19 on work loss in the United States- A retrospective database analysis
Judy, J., Yehoshua, A., Gouveia-Pisano, J. A., Brook, R. A., Kleinman, N. L., Drnach, A. A., Rosenberg, E. M., Ghanjanasak, T., Winter, D. A., Dai, F., et al. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2379056 · Cited by 5
Bejko, D., Ernst, C., Vergison, A., Stranges, S., Zeegers, M. P., & Mossong, J. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.05.059 · Cited by 6
Bennett, C., Chau, G., Clayton, E., Chu, L., Alvarez, J., Hidalgo, A. B., Palanpurwala, K., Plested, J. S., Zhu, M., Cloney-Clark, S., et al. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106428 · Cited by 5
Essential Logic and Facts Behind the Expansion of the Genetic Code: A Critical Assessment
Luu, H. T. L., Karbalaei‐Heidari, H. R., & Budiša, N. (2025) · ChemCatChem · doi:10.1002/cctc.202500809 · Cited by 9
Morris, J. S. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae280 · Cited by 6
Rahman, N. A., King, T. L., Peariasamy, K. M., & Sivasampu, S. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126465 · Cited by 5
Ebanks, D., Faustini, S. E., Shields, A. M., Parry, H., Moss, P. A. H., Plant, T. D., Richter, A. G., & Drayson, M. T. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.07.020 · Cited by 4
“All 48 serum samples that were positive in he AbC-19 TM LFT were positive against three variant LFTs (Alpha, eta and Gamma) albeit at lower levels; taking the mean of all he variant LFT scores these means were a percentage of the mean uhan score 88%, 71% and 49% respectively for PFZ, AZ and NI. n the Pfizer group 100%…”
InfluentialLopez, E., Haycroft, E., Adair, A., et al. (2021) · medRxiv · doi:10.1101/2021.03.20.21254037 · Cited by 6
Kolber, M. R., Fritsch, P., Price, M., Singer, A. G., Young, J. C., Dugré, N., Bradley, S., & Nickonchuk, T. (2021) · Canadian Family Physician · doi:10.46747/cfp.6703185 · Cited by 4
Makanut, S., Wangteeraprasert, A., Jitpewngam, W., Ngoenkam, J., & Pongcharoen, S. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.017 · Cited by 5
“BNT162b2 had an efficacy of 95 % in preventing COVID-19 7 days after the second dose, with minor adverse reactions such as pain at the injection site, fatigue and headache [5].”
Gül, F., Kasapoğlu, U. S., Sabaz, M. S., Ay, P., Oktay, B. D., Çalışkan, G., Demir, N., Sayan, İ., Kabadayı, F., Altuntaş, G., et al. (2023) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2023.2023-6-90 · Cited by 9
“The median APACHE II (18 [14-24] vs. 15 [10-21]; p < 0.001) and SOFA (5 [4-8] vs. 5[3-8]; p = 0.024) scores were higher in the two-dose CoronaVac group than in the unvaccinated group (Table 2).”
BackgroundInfluentialThe COVID-19 Vaccine in Clinical Trials: Where Are We Now?
Jiang, H.-D., Li, J., Zhang, P., Huo, X., & Zhu, F. (2021) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000003 · Cited by 6
(2021) · doi:10.1101/2021.07.20.21260849 · Cited by 5
“The reduction of 90% in the incidence of COVID-19 after vaccination with the Pfizer BNT162b2 vaccine in the general population (2,3) or in SARS-Cov-2 RNA detection in vaccinated versus non-vaccinated health workers (4) might not be reproduced in vaccinated hemodialysis patients.”
BackgroundDas, R., Medeiros, J., Krishna, J., Munugoti, S., Dutta, R., Devarajan, A., Ghosh, A., & Thayumanavan, S. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00205 · Cited by 5
EFFECTS OF VACCINATION ON THE TRANSMISSION DYNAMICS OF COVID-19 IN DOUGHERTY COUNTY OF GEORGIA, USA
Pantha, B., Mohammed-Awel, J., & Vaidya, N. K. (2022) · Journal of Biological Systems · doi:10.1142/s021833902250019x · Cited by 5
Visualisations and narratives in digital media. Methods and current trends
Freixa, P., Codina, L., Pérez-Montoro, M., & Guallar, J. (2022) · doi:10.3145/indocs.2022.0 · Cited by 6
Zuckerman, N. S., Nemet, I., Kliker, L., Atari, N., Lustig, Y., Bucris, E. D., Bar-Ilan, D., Geva, M., Sorek‐Abramovich, R., Weiner, C., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.45.2100974 · Cited by 5
“The reasons for this can include higher infectiveness or transmissibility of some VOC compared with others, as was recently suggested for the Delta variant [18].”
BackgroundInfluentialEzzikouri, S., Raji, T., Majidi, H., Redwane, S., Aqillouch, S., Abdulaziz, M., Aragaw, M., Fallah, M. P., Sembuche, S. L., Batcho, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-58498-6 · Cited by 7
Acute and Chronic Demyelinating Neuropathies After COVID-19 Vaccination: A Report of 4 Cases
Dennis, E., Hartman, E., Cortes-Penfield, N. W., Piccione, E. A., & Thaisetthawatkul, P. (2023) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0000000000000418 · Cited by 6
Stehlik, P., Dowsett, C., Camacho, X., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-079071 · Cited by 5
Yu, R., Bai, Y., Zhang, L., Zhou, P., Zhang, Z., Yang, J. L., Lu, Y., Wang, D., Peng, Y., Li, D., et al. (2025) · Journal of Virology · doi:10.1128/jvi.00849-25 · Cited by 7
“This design strategy has been implemented in various coronavirus vaccines, including the mRNA vaccines of Moderna/BioNTech, Johnson & Johnson’s adenoviral vector vaccine, and Novavax’s recombinant protein vaccine (11–14).”
Albichr, I. S., Mzougui, S., Devresse, A., Georgery, H., Goffin, E. J., Kanaan, N., Yombi, J. C., Belkhir, L., Greef, J. D., Scohy, A., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17186 · Cited by 6
Raw, R. K., Rees, J. C., & Chadwick, D. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001053 · Cited by 4
“Global vaccination efforts against SARS-CoV-2 began in late 2020, with BNT162b2/Pfizer [1], mRNA-1273/Moderna [2], and ChAdOx1/AstraZeneca [3] vaccines applied predominantly in the UK population.”
BackgroundChemical Strategy and AI-Enabled Peptide Vaccine Development
Wang, X.-X., Su, J.-Y., & Li, Y.-M. (2026) · JACS Au · doi:10.1021/jacsau.6c00008 · Cited by 5
Amara, A., Trabelsi, S., Hai, A., Zaidi, S. H. H., Siddiqui, F., & Alsaeed, S. A. (2024) · Pathogens · doi:10.3390/pathogens13121070 · Cited by 6
“…undertaken after the conclusion of clinical trials and the development of mRNA vaccines, and while these interventions significantly reduced severe disease and death, the pandemic perpetually persists in various parts of the world due to emerging variants of concern such as Delta and Omicron [6].”
Moliva, J. I., Andrew, S. F., Flynn, B. J., Wagner, D. A., Foulds, K. E., Gagné, M., Flebbe, D. R., Lamb, E., Provost, S. J., Marquez, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.22.567930 · Cited by 5
Rotaviruses and Rotavirus Vaccines: Special Issue Editorial
Patton, J. T., & Desselberger, U. (2024) · Viruses · doi:10.3390/v16111665 · Cited by 5
Respiratory mucosal vaccines: Applications, delivery strategies and design considerations
Shi, T., Ye, Y., Fan, Z., Yang, Q., Ma, Y., & Zhu, J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118326 · Cited by 9
Ketaren, N. E., Mast, F. D., Fridy, P. C., Olivier, J. P., Sanyal, T., Sali, A., Chait, B. T., Rout, M. P., & Aitchison, J. D. (2024) · eLife · doi:10.7554/elife.89423.3 · Cited by 5
“SARS-CoV-2 displays three structural proteins that are potential targets for therapeutic intervention, but the primary focal point of vaccine development and many therapeutic strategies is the spike surface glycoprotein, which the virus uses to gain cell entry by attaching to the host cell angiotensin-converting enzym…”
Miyazaki, H., Watanabe, D., Ito, Y., Ikeda, S., Okamoto, N., Tokunaga, E., Ku, Y., Ooi, M., Hoshi, N., & Kodama, Y. (2023) · Indian Journal of Gastroenterology · doi:10.1007/s12664-023-01386-0 · Cited by 4
Wong, M., Liu, J. T., Budylowksi, P., Yue, F. Y., Li, Z., Rini, J. M., Carlyle, J. R., Zia, A., Ostrowski, M., & Martín, A. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108963 · Cited by 8
“BNT162b2 is generally delivered under a two-dose prime-boost regimen, exhibiting ~95% vaccine efficacy when doses are administered 21 days apart [1,2].”
Rolfes, M. A. R., Talbot, H. K., Morrissey, K. G., et al. (2023) · medRxiv · doi:10.1101/2023.10.20.23297317 · Cited by 5
Galhaut, M., Lundberg, U., Marlin, R., Schlegl, R., Seidel, S., Bartuschka, U., Heindl-Wruss, J., Relouzat, F., Langlois, S., Dereuddre‐Bosquet, N., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00488-w · Cited by 7
Search for better COVID vaccines confounded by existing rollouts
Dolgin, E. (2021) · Nature · doi:10.1038/d41586-021-00015-0 · Cited by 5
A Study on Novel Corona Virus Disease (COVID-19)
Singh, H., Kumar, S., & Kumar, R. (2021) · Asian Journal of Engineering and Applied Technology · doi:10.51983/ajeat-2021.10.1.2801 · Cited by 4
Hayashi, H., Sun, J., Yanagida, Y., Otera, T., Tai, J. A., Nishikawa, T., Yamashita, K., Sakaguchi, N., Yoshida, S., Baba, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-40172-y · Cited by 7
Bignon, E., Marazzi, M., & Monari, A. (2022) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.2c01102 · Cited by 6
Golshani, M., Svobodová, L. M., Štěpánek, L., Zeman, J., Nytrová, P., Posová, H., Petrásková, P., Novotná, O., Nováková, M., Černý, V., et al. (2022) · Vaccines · doi:10.3390/vaccines10122038 · Cited by 5
“BNT162b2 (also known as Comirnaty) is a lipid nanoparticle (LNP)—encapsulated mRNA vaccine encoding the modified SARS-CoV-2 full-length spike (two proline mutations are applied to lock it in the prefusion conformation) [9].”
BackgroundInfluentialZhou, X., Wang, Y., Huang, B., Feng, R., Zhou, X., Li, C., Zhang, X., Shao, M., Gan, Y., Jin, Y., et al. (2022) · Immunology · doi:10.1111/imm.13572 · Cited by 6
“The primary endpoint was the safety of vaccination, which was determined by the occurrence of adverse events after each dose [12, 22].”
BackgroundChoi, J. Y., Mahadik, B. P., & Fisher, J. P. (2021) · Essays in Biochemistry · doi:10.1042/ebc20200105 · Cited by 5
Bannick, M. S., Gao, F., Brown, E. R., & Janes, H. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad046 · Cited by 5
The Immune Response to SARS-CoV-2: Mechanisms, Aging, Sequelae, and Vaccines
Alarcón, M. A., & Espinoza, C. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220304231537 · Cited by 5
Safety and Efficacy of Preventative COVID Vaccines: The StopCoV StudyPreprint
Walmsley, S. L., Szadkowski, L., Wouters, B. G., Clarke, R., Colwill, K., Rochon, P. A., Brudno, M., Ravindran, R., Raboud, J., McGeer, A., et al. (2022) · SSRN Electronic Journal · doi:10.1101/2022.02.09.22270734 · Cited by 8
“[1-4] Few people over age 70 were included in the randomized vaccine trials([1]), yet older persons, especially those with comorbidity, have higher risk of mortality from COVID-19 infection.”
BackgroundMasci, G. M., Izzo, A., Bonito, G., Marchitelli, L., Guiducci, E., Ciaglia, S., Lucchese, S., Corso, L., Valenti, A., Malzone, L., et al. (2023) · La radiologia medica · doi:10.1007/s11547-023-01664-z · Cited by 9
Wasserbauer, M., Hlava, Š., Trojánek, M., Šťovíček, J., Milota, T., Drábek, J., Koptová, P., Cupkova, A., Pichlerová, D., Frýbová, B., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273612 · Cited by 5
“The pilot study evaluated the effect of vaccination with BNT162b2 in the context of confirmed COVID-19 cases from all participants in a two-month follow-up after vaccination [26].”
MethodCOVID-19 Breakthrough Infections Among People With HIV: A Statewide Cohort Analysis
Yang, X., Zhang, J., Chen, S., Liu, Z., Poland, G. A., Olatosi, B., Weissman, S., & Li, X. (2024) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003475 · Cited by 4
Evaluating and optimizing COVID-19 vaccination policies: a case study of SwedenPreprint
Sjödin, H., Rocklöv, J., & Britton, T. (2021) · medRxiv · doi:10.1101/2021.04.07.21255026 · Cited by 5
Shumilov, E., Aperdannier, L., Schmidt, N. C., Szuszies, C. J., Neeße, A., Hoffknecht, P., Khandanpour, C., Mikesch, J., Stelljes, M., Boeckel, G. R., et al. (2022) · Cancers · doi:10.3390/cancers14153746 · Cited by 5
“Despite the high protection rate of COVID19 vaccines in the general population [4], considerable uncertainty still exists regarding their efficacy and the risk of COVID-19 for cancer patients.”
BackgroundOver- and under-estimation of vaccine effectiveness
De-Leon, H., & Aran, D. (2025) · BMC Medical Research Methodology · doi:10.1186/s12874-025-02611-4 · Cited by 6
“To model vaccine effectiveness, we assumed the protection from the vaccine starts seven days after the first dose and reached its maximum after seven days from the second dose [3, 26].”
Tian, X., Zhang, Y., He, Z., Li, S., Yan, D., Zhu, Z., Wan, Y., & Wang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.875236 · Cited by 6
“Among different types of COVID-19 vaccines, the mRNA vaccines displayed extraordinary performance in preventing COVID-19 according to clinical trials (6, 7).”
BackgroundDam, S., Tscherne, A., Engels, L., Sutter, G., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2025) · Scientific Reports · doi:10.1038/s41598-025-95479-9 · Cited by 8
“Alternatively, the synthetic poly-epitope antigen can also be delivered by other antigen delivery systems, such as mRNA-based vaccine preparations 76 .”
Guiding design and performance of nonviral nucleic acid delivery vehicles via machine learning
Hutchinson, J. A., Panda, S., Rosales, P. D., Sowada, J. P., Willis, M. S., Leyden, M. C., Daoutidis, P., & Reineke, T. M. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115739 · Cited by 10
Skrzat‐Klapaczyńska, A., Kowalska, J. D., Paciorek, M., Puła, J., Bieńkowski, C., Krogulec, D., Stengiel, J., Pawełczyk, A., Perlejewski, K., Osuch, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10122158 · Cited by 5
“Healthcare workers (HCWs), being on the front lines, were deemed as a group with the highest risk of exposure to COVID-19, and a significant number of them were reported to be infected [6].”
BackgroundInfluentialValanparambil, R. M., Lai, L., Johns, M. A., Davis-Gardner, M. E., Linderman, S. L., McPherson, T., Chang, A., Akhtar, A., Gamarra, E. L. B., Matia, H., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00779-8 · Cited by 4
Aleman, A., Oekelen, O. V., Upadhyaya, B., Agte, S., Kappes, K., Beach, K. F., Srivastava, K., Gleason, C., PVI study group, Wang, B., et al. (2021) · medRxiv · doi:10.1101/2021.05.15.21256814 · Cited by 5
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.